ReviewOncoTargets and therapy2016
Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives.
Review in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Comprehensive Overview of Gastric Cancer Immunohistochemistry: Key Biomarkers, Advanced Detection Methods, and Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
- Human epidermal growth factor receptor 2 expression and socio-demographic, clinical, and histopathological characteristics in gastric carcinoma at St Francis Hospital Nsambya, Uganda.BMC gastroenterology · 2025Article
- A novel anti-HER2/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs.Investigational new drugs · 2025Article
- Blocking the Hormone Receptors Modulates NLRP3 in LPS-Primed Breast Cancer Cells.International journal of molecular sciences · 2023Article
- High-throughput membrane-anchored proteome screening reveals PIEZO1 as a promising antibody-drug target for human esophageal squamous cell carcinoma.Cancer medicine · 2022Article
- Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy.Frontiers in oncology · 2022Article
- Downregulation of miR-375 contributes to ERBB2-mediated VEGFA overexpression in esophageal cancer.Journal of Cancer · 2021Article
- Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review.Oncology and therapy · 2020Article
- Advances in targeted therapy for esophageal cancer.Signal transduction and targeted therapy · 2020Review
- Xanthohumol Inhibits the Growth of Keratin 18-Overexpressed Esophageal Squamous Cell CarcinomaFrontiers in cell and developmental biology · 2020Article
- Esophageal cancer research today and tomorrow: Lessons from algae and other perspectives.AIMS genetics · 2018Review
- "Targeted" Chemotherapy for Esophageal Cancer.Frontiers in oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The addition of trastuzumab to the treatment of a subset of patients with advanced gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to confer clinical benefit; however, questions remain over the optimal methods for defining and selecting such patients. This review provides an overview of current standards for assessing HER2 positivity, the evolving treatment landscape for HER2-positive gastric and esophageal cancers and the challenges and potential future directions in optimal patient selection for HER2-targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.